{"id":60586,"date":"2026-03-23T16:05:44","date_gmt":"2026-03-23T08:05:44","guid":{"rendered":"https:\/\/flcube.com\/?p=60586"},"modified":"2026-03-23T16:05:45","modified_gmt":"2026-03-23T08:05:45","slug":"biokin-pharmas-bl-arc002-wins-nmpa-approval-first-in-class-antibody-radionuclide-conjugate-enters-solid-tumor-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60586","title":{"rendered":"Biokin Pharma&#8217;s BL\u2011ARC002 Wins NMPA Approval \u2013 First\u2011in\u2011Class Antibody\u2011Radionuclide Conjugate Enters Solid Tumor Trials"},"content":{"rendered":"\n<p><strong>Sichuan Biokin Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>) announced that its <strong>BL\u2011ARC002 injection<\/strong>, a <strong>Category 1 innovative antibody\u2011radionuclide conjugate (ARC)<\/strong>, has received <strong>NMPA clinical trial approval<\/strong> for <strong>advanced solid tumors<\/strong> \u2013 positioning the <strong>potentially first\u2011in\u2011class<\/strong> candidate with <strong>fully independent IP rights<\/strong> at the forefront of China&#8217;s emerging targeted radiotherapy field.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>BL\u2011ARC002 injection<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Category 1 innovative drug \u2013 <strong>antibody\u2011radionuclide conjugate (ARC)<\/strong><\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced solid tumors<\/td><\/tr><tr><td><strong>IP Status<\/strong><\/td><td><strong>Fully independent intellectual property rights<\/strong> (Biokin\u2011owned)<\/td><\/tr><tr><td><strong>Global Positioning<\/strong><\/td><td><strong>Potentially first\u2011in\u2011class ARC<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-technology-innovation\">Product Profile &amp; Technology Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Platform:<\/strong> <strong>Antibody\u2011radionuclide conjugate (ARC)<\/strong> \u2013 next\u2011generation targeted radiotherapy<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong><\/li>\n\n\n\n<li><strong>Antibody\u2011mediated precise targeted delivery<\/strong> \u2013 tumor\u2011specific antigen binding<\/li>\n\n\n\n<li><strong>Radionuclide payload<\/strong> \u2013 potent tumor\u2011killing radioisotope delivery<\/li>\n\n\n\n<li><strong>Differentiation vs. Traditional Radioligand Therapy:<\/strong><\/li>\n\n\n\n<li><strong>Stronger target specificity<\/strong> \u2013 antibody\u2011driven vs. small\u2011molecule ligand<\/li>\n\n\n\n<li><strong>Higher tumor accumulation<\/strong> \u2013 enhanced pharmacokinetic profile<\/li>\n\n\n\n<li><strong>Superior resistance to drug resistance<\/strong> \u2013 radionuclide mechanism bypasses common resistance pathways<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-context-amp-strategic-positioning\">Competitive Context &amp; Strategic Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Traditional Radioligand Therapy (e.g., Pluvicto, Lutathera)<\/th><th>BL\u2011ARC002 ARC Approach<\/th><\/tr><\/thead><tbody><tr><td><strong>Targeting Mechanism<\/strong><\/td><td>Small\u2011molecule ligands (PSMA, SSTR2)<\/td><td><strong>Antibody\u2011mediated<\/strong> \u2013 potentially broader antigen repertoire<\/td><\/tr><tr><td><strong>Tumor Specificity<\/strong><\/td><td>Moderate (normal tissue expression of PSMA\/SSTR2)<\/td><td><strong>Higher specificity<\/strong> \u2013 antibody selectivity vs. small molecule<\/td><\/tr><tr><td><strong>Tumor Accumulation<\/strong><\/td><td>Limited by rapid renal clearance<\/td><td><strong>Enhanced accumulation<\/strong> \u2013 antibody pharmacokinetics<\/td><\/tr><tr><td><strong>Resistance Profile<\/strong><\/td><td>Resistance emerges via antigen loss\/heterogeneity<\/td><td><strong>Radionuclide crossfire effect<\/strong>; antibody\u2011mediated delivery reduces resistance mechanisms<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Radiotherapy Market Dynamics:<\/strong> Global radioligand therapy market <strong>US$3+ billion<\/strong> (2024); projected <strong>US$10+ billion by 2030<\/strong> driven by prostate cancer (Pluvicto) and neuroendocrine tumor (Lutathera) approvals; ARC technology represents <strong>next\u2011generation evolution<\/strong> beyond small\u2011molecule radioligands.<\/li>\n\n\n\n<li><strong>Biokin Innovation Validation:<\/strong> First\u2011in\u2011class ARC with <strong>fully independent IP<\/strong> demonstrates Biokin&#8217;s <strong>antibody engineering and radiochemistry capabilities<\/strong>; Category 1 status supports priority regulatory pathways and potential government funding; Chengdu\u2011based development aligns with Sichuan province biotech cluster growth.<\/li>\n\n\n\n<li><strong>Solid Tumor Opportunity:<\/strong> Initial indication <strong>advanced solid tumors<\/strong> (basket trial design) enables rapid efficacy signal detection across multiple histologies; likely targets include <strong>lung, breast, gastric, pancreatic cancers<\/strong> with validated antibody targets (HER2, EGFR, CLDN18.2); biomarker\u2011driven patient selection critical for radionuclide efficacy.<\/li>\n\n\n\n<li><strong>Clinical Development Trajectory:<\/strong> Phase I safety\/dose\u2011finding <strong>H2 2026<\/strong>; radionuclide therapy requires specialized clinical infrastructure (radiation safety, nuclear medicine expertise); partnership with <strong>China\u2011based nuclear medicine centers<\/strong> essential for trial execution; Phase II proof\u2011of\u2011concept <strong>2028\u20112029<\/strong>.<\/li>\n\n\n\n<li><strong>Partnership &amp; Global Potential:<\/strong> First\u2011in\u2011class ARC platform highly attractive for <strong>global radiopharma partnerships<\/strong> (Novartis, Bayer, AstraZeneca actively expanding radioligand portfolios); potential deal structure: <strong>US$300\u2011500 million upfront<\/strong> for ex\u2011China rights upon Phase I safety demonstration; Biokin retains China commercialization rights.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, technology validation, and partnership potential for BL\u2011ARC002. Actual results may differ due to risks including radionuclide safety management, manufacturing complexity for antibody\u2011radionuclide conjugates, and competitive dynamics in the rapidly evolving targeted radiotherapy landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688506_20260323_1K8Y.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688506_20260323_1K8Y.\"><\/object><a id=\"wp-block-file--media-fc99f360-4bed-4904-ba9f-3718dc7d0d60\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688506_20260323_1K8Y.pdf\">688506_20260323_1K8Y<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688506_20260323_1K8Y.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-fc99f360-4bed-4904-ba9f-3718dc7d0d60\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its BL\u2011ARC002 injection, a Category 1&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[151,62,857],"class_list":["post-60586","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-biokin-pharmaceutical","tag-clinical-trial-approval-initiation","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biokin Pharma&#039;s BL\u2011ARC002 Wins NMPA Approval \u2013 First\u2011in\u2011Class Antibody\u2011Radionuclide Conjugate Enters Solid Tumor Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its BL\u2011ARC002 injection, a Category 1 innovative antibody\u2011radionuclide conjugate (ARC), has received NMPA clinical trial approval for advanced solid tumors \u2013 positioning the potentially first\u2011in\u2011class candidate with fully independent IP rights at the forefront of China&#039;s emerging targeted radiotherapy field.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60586\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biokin Pharma&#039;s BL\u2011ARC002 Wins NMPA Approval \u2013 First\u2011in\u2011Class Antibody\u2011Radionuclide Conjugate Enters Solid Tumor Trials\" \/>\n<meta property=\"og:description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its BL\u2011ARC002 injection, a Category 1 innovative antibody\u2011radionuclide conjugate (ARC), has received NMPA clinical trial approval for advanced solid tumors \u2013 positioning the potentially first\u2011in\u2011class candidate with fully independent IP rights at the forefront of China&#039;s emerging targeted radiotherapy field.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60586\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T08:05:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-23T08:05:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60586#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60586\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biokin Pharma&#8217;s BL\u2011ARC002 Wins NMPA Approval \u2013 First\u2011in\u2011Class Antibody\u2011Radionuclide Conjugate Enters Solid Tumor Trials\",\"datePublished\":\"2026-03-23T08:05:44+00:00\",\"dateModified\":\"2026-03-23T08:05:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60586\"},\"wordCount\":505,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biokin Pharmaceutical\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60586#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60586\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60586\",\"name\":\"Biokin Pharma's BL\u2011ARC002 Wins NMPA Approval \u2013 First\u2011in\u2011Class Antibody\u2011Radionuclide Conjugate Enters Solid Tumor Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-23T08:05:44+00:00\",\"dateModified\":\"2026-03-23T08:05:45+00:00\",\"description\":\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its BL\u2011ARC002 injection, a Category 1 innovative antibody\u2011radionuclide conjugate (ARC), has received NMPA clinical trial approval for advanced solid tumors \u2013 positioning the potentially first\u2011in\u2011class candidate with fully independent IP rights at the forefront of China's emerging targeted radiotherapy field.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60586#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60586\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60586#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biokin Pharma&#8217;s BL\u2011ARC002 Wins NMPA Approval \u2013 First\u2011in\u2011Class Antibody\u2011Radionuclide Conjugate Enters Solid Tumor Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biokin Pharma's BL\u2011ARC002 Wins NMPA Approval \u2013 First\u2011in\u2011Class Antibody\u2011Radionuclide Conjugate Enters Solid Tumor Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its BL\u2011ARC002 injection, a Category 1 innovative antibody\u2011radionuclide conjugate (ARC), has received NMPA clinical trial approval for advanced solid tumors \u2013 positioning the potentially first\u2011in\u2011class candidate with fully independent IP rights at the forefront of China's emerging targeted radiotherapy field.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60586","og_locale":"en_US","og_type":"article","og_title":"Biokin Pharma's BL\u2011ARC002 Wins NMPA Approval \u2013 First\u2011in\u2011Class Antibody\u2011Radionuclide Conjugate Enters Solid Tumor Trials","og_description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its BL\u2011ARC002 injection, a Category 1 innovative antibody\u2011radionuclide conjugate (ARC), has received NMPA clinical trial approval for advanced solid tumors \u2013 positioning the potentially first\u2011in\u2011class candidate with fully independent IP rights at the forefront of China's emerging targeted radiotherapy field.","og_url":"https:\/\/flcube.com\/?p=60586","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-23T08:05:44+00:00","article_modified_time":"2026-03-23T08:05:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60586#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60586"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biokin Pharma&#8217;s BL\u2011ARC002 Wins NMPA Approval \u2013 First\u2011in\u2011Class Antibody\u2011Radionuclide Conjugate Enters Solid Tumor Trials","datePublished":"2026-03-23T08:05:44+00:00","dateModified":"2026-03-23T08:05:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60586"},"wordCount":505,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biokin Pharmaceutical","Clinical trial approval \/ initiation","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60586#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60586","url":"https:\/\/flcube.com\/?p=60586","name":"Biokin Pharma's BL\u2011ARC002 Wins NMPA Approval \u2013 First\u2011in\u2011Class Antibody\u2011Radionuclide Conjugate Enters Solid Tumor Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-23T08:05:44+00:00","dateModified":"2026-03-23T08:05:45+00:00","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its BL\u2011ARC002 injection, a Category 1 innovative antibody\u2011radionuclide conjugate (ARC), has received NMPA clinical trial approval for advanced solid tumors \u2013 positioning the potentially first\u2011in\u2011class candidate with fully independent IP rights at the forefront of China's emerging targeted radiotherapy field.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60586#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60586"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60586#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biokin Pharma&#8217;s BL\u2011ARC002 Wins NMPA Approval \u2013 First\u2011in\u2011Class Antibody\u2011Radionuclide Conjugate Enters Solid Tumor Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60586"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60586\/revisions"}],"predecessor-version":[{"id":60589,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60586\/revisions\/60589"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}